Skip to main content

Table 1 Main studies focusing on Incidence, outcomes, and prognostic factors of COVID-19 in rheumatoid arthritis and spondiloarthritis patients

From: Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders

First author

Study design

Sample size

RA patients

SpA patients

PsA patients

Outcome of COVID-19 patients with inflammatory arthropathies

Prognostic factors

FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors

Observational study

694

213

165

70

Severe COVID-19/hospitalization in RA: 29; SpA: 5; PsA: 6

Death in RA: 20; SpA: 1; PsA: 3

Older age

Comorbidities

Longer term of GCs

Gianfrancesco et al.

Observational study

600

225

48

74

Severe COVID-19/hospitalization in RA: 104; SpA: 16; PsA: 22

Death in the overall cohort including also CTD: 55

Older age

Comorbidities

Higher doses of GCs

Hasseli et al.

Retrospective observational study

468

146

125

*

Severe COVID-19/hospitalization in RA: 79; SpA: 20 severe COVID-19

Death in the overall cohort including also CTD: 19

Older age

Comorbidities

Treatment with GCs at doses > 5 mg/day

Moderate to high RMD disease activity

Montero et al.

Retrospective observational study

62

20

16

*

Severe COVID-19/hospitalization in RA: 15; SpA: 11

Death in the overall cohort including also CTD: 10

Male Gender

Preexisting lung disease

Treatment with GC at dose > 5 mg/day

Pang et al.

Observational study

21

15

–

–

Severe COVID-19/hospitalization in RA: 15

0 death

Comorbidities

Cheng et al.

Observational study

5

4

–

–

5 hospitalised

0 death

Not reported

Marques et al.

Observational study

334

95

45

23

110 hospitalised

28 death

Age > 50 years

Treatment with GCs and cyclophosphamide

  1. GCs: Glucocorticoids; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; RMD: Rheumatic Diseases; SpA: Spondiloarthritis
  2. *In these studies, PsA patients are included in the SpA group